KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 102 filers reported holding KALA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $0 | -100.0% | 1,015 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 1,015 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | -90.0% | 1,015 | -72.7% | 0.00% | – |
| Q3 2021 | $10,000 | -94.0% | 3,713 | -88.2% | 0.00% | -100.0% |
| Q2 2021 | $166,000 | -33.9% | 31,375 | -15.6% | 0.00% | -50.0% |
| Q1 2021 | $251,000 | -0.4% | 37,175 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $252,000 | +514.6% | 37,175 | +588.4% | 0.00% | – |
| Q3 2020 | $41,000 | -28.1% | 5,400 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $57,000 | +29.5% | 5,400 | +9.1% | 0.00% | – |
| Q1 2020 | $44,000 | – | 4,950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |